Month: September 2025

Sampo plc, stock exchange release, 24 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 23 September 2025                                                  On 23 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  4,126 9.62 AQEU    147,419 9.62 CEUX  39,739 9.63 TQEX  206,790 9.62 XHELTOTAL 398,074 9.62  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

Enabling Smart Human Detection and Interactive Awareness to Elevate AI in Endpoint Devices TAINAN, Taiwan, Sept. 24, 2025 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced that its WiseEye™ ultralow power AI sensing solution has been successfully adopted in Acer’s Swift Edge 14 AI series, a slim and lightweight AI notebook that has already entered mass production. Himax’s WiseEye solution equips Acer’s AI notebook with advanced human detection and interactive awareness features, including Human Presence Detection (HPD) and health reminder alerts such as for prolonged use or close viewing distance as well as posture correction notifications. Additionally, it introduces a multi-screen...

Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovationThe fund will remain focused on Sanofi’s key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities that support the company’s long-term strategy Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companiesParis, September 24, 2025. Sanofi Ventures has announced an additional $625 million multi-year capital commitment from Sanofi, increasing its total assets under management to over $1.4 billion. This new commitment to the evergreen venture fund builds on more than a decade of investing in innovative biotech and digital health companies that align with Sanofi’s long-term...

BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc.  (NASDAQ: LNTH) and GE HealthCare (NASDAQ: GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus’ piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The agreement includes the transfer of regulatory dossiers, manufacturing competencies and technical support to enable GE HealthCare to drive clinical development in Japan, towards potential regulatory submissions and commercial launch. GE HealthCare will draw on its extensive manufacturing network and...

Applied is leveraging its leadership in materials engineering to provide the highest quality waveguides for augmented reality glasses SANTA CLARA, Calif. and SINGAPORE, Sept. 23, 2025 (GLOBE NEWSWIRE) — Applied Materials, Inc. today announced a strategic collaboration with GlobalFoundries (GF) to establish a state-of-the-art waveguide fabrication facility at GF Singapore to accelerate the emerging photonics inflection driven by AI. The collaboration marks a significant milestone in the evolution of photonics as a foundational technology for next-generation AI applications, including augmented reality (AR) and human-centric digital experiences that require ultra-efficient, lightweight and high-performance optical systems. Applied Materials will develop waveguide components with GF as its high-volume manufacturing partner in Singapore,...

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at an offering price of $67.67 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 960,542 shares of common stock at the purchase price of $67.669 per pre-funded warrant, which represents the offering price per share for the common stock less a $0.001 per share exercise price. The gross proceeds to Monopar from the offering net of the anticipated Stock Repurchase (as defined below), but before deducting the underwriting...

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (link), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain. In the Letter to the Editor, the authors explain that the earlier conclusion from the Phase 2 ALXN1840-WD-204 study (NCT04573309)...

VANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC; OTC: ZCTSF) (the “Company”) is pleased to announce that it has closed the first tranche of its previously announced private placement financing by issuing a total of 38,449,335 units (“Units”) at a price of $0.06 per Unit for gross proceeds of $2,306,960. The Company anticipates it will complete the final tranche by September 29, 2025. Each Unit consists of one common share (a “Share”) and one common share purchase warrant (a “Warrant”), with each Warrant exercisable at $0.10 per Share for a period of two years from the date of issue (the “Expiry Date”). The Company has the right to accelerate the Expiry Date if, at any time, the volume weighted average price of the Shares on the principal exchange or market on which the Shares trade...

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) — Mural Oncology plc, (Nasdaq: MURA) (“Mural”), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the “Irish Takeover Rules”), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the “Proxy Statement”) and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”) and Mural entered into a definitive transaction agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued...